Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men

What Was Tested

The paper reports a study of DSIP (delta sleep-inducing peptide) and ACTH (Corticotropin), published as a randomized controlled trial.

Delta-sleep-inducing peptide (DSIP) is a well-known inhibitor of pituitary ACTH secretion.

The results obtained after the administration of DSIP at time 0 and at -60 min were similar.

Who Took Part

The abstract describes 8 men taking part.

By PubMed's age tags, the people studied were adults, men only.

In an additional 7 subjects, DSIP or placebo was given 60 min before hypertonic saline or the orthostatic test.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The men were allocated by chance, so the DSIP (delta sleep-inducing peptide) group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the DSIP (delta sleep-inducing peptide) group a baseline to be compared against.

In different occasions, a 10-min infusion of normal saline (placebo) was given instead of DSIP.

What Was Measured

PubMed files the paper under topics including Adrenocorticotropic Hormone, Arginine Vasopressin, Blood Pressure, Delta Sleep-Inducing Peptide, Heart Rate, Osmolar Concentration and Saline Solution, Hypertonic.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of DSIP (delta sleep-inducing peptide) and ACTH (Corticotropin) in 8 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (Hormone research), a journal based in Switzerland.

More context: the DSIP (delta sleep-inducing peptide) compound page and the ACTH (Corticotropin) compound page, all human trials.